Rigel製藥 RIGL 深 滬
已收盤 10-31 16:00:00 美东时间
31.58
-0.040
-0.13%
華盛通- 最 高32.8999
- 今 開32.00
- 成交量 47.34万股
- 最 低 31.21
- 昨 收 31.62
- 總市值 5.66亿
- 52周最高 43.7181
- 市盈率 靜 31.94
- 換手率 2.64%
- 52周最低 14.63
- 委 比 -97.80%
- 總股本 1793.73万
- 歷史最高 114.40
- 量 比 1.36
- 振 幅 5.34%
- 歷史最低 6.40
- 每 手 1
- 風險率 6.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高186美元！戴尔科技或多家机构上调目标价； 高盛上调超微公司目标价至210美元
今日重点评级关注：富国银行：维持Kyverna Therapeutics"超配"评级，目标价从24美元升至27美元；Chardan Capital：维持Oculis Holding"买入"评级，目标价从33美元升至51美元
10-09 10:51
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57 price target.
10-08 22:19
Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday
U.S. stocks were lower, with the Dow Jones index falling more than 150 points o...
09-25 02:18
Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
Rigel Pharmaceuticals shares are trading higher after the company reported bett...
08-06 20:31
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., July 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceutical...
07-07 20:05
Rigel Pharmaceuticals Approves Equity Plan Amendment
Rigel ( ($RIGL) ) has issued an announcement. On May 22, 2025, Rigel Pharmaceut...
05-24 04:49
Rigel Pharmaceuticals To Present Final GAVRETO Phase 1/2 ARROW Study Data In RET Fusion-Positive NSCLC And Solid Tumors, Along With Supportive REZLIDHIA Data For mIDH1 R/R AML At ASCO And EHA 2025 Conferences
Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with
05-23 05:36
Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 financial results.
Rigel Pharmaceuticals shares are trading higher after the company reported bett...
05-07 04:56
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceutica...
04-04 20:05
